FF
ITCI

FourThought Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

FourThought Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$41K Hold
889
– – 0.01% 668
2022
Q2 		$51K Hold
889
– – 0.01% 605
2022
Q1 		$54K Buy
+889
New +$46.2K 0.01% 643

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FourThought Financial's ITCI Position: Q3 2022 in Review

FourThought Financial held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q3 2022 at 889 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #668.

FourThought Financial first reported a position in ITCI in Q1 2022 and has held it in 3 quarters since. The position peaked at $54K in Q1 2022. 274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

  • FourThought Financial held 889 shares of Intra-Cellular Therapies Inc. worth $41K as of Q3 2022.
  • FourThought Financial left its Intra-Cellular Therapies Inc. share count unchanged in Q3 2022.
  • Intra-Cellular Therapies Inc. made up 0.01% of FourThought Financial's portfolio in Q3 2022, its #668 holding.
  • FourThought Financial first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and has held it in 3 quarters since.
  • FourThought Financial's Intra-Cellular Therapies Inc. position peaked at $54K in Q1 2022.
  • 274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.